Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
55.54
+0.21 (0.38%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 54.82 - 57.12
52 week 44.76 - 112.57
Open 56.07
Vol / Avg. 391,697.00/815,682.00
Mkt cap 4.20B
P/E     -
Div/yield     -
EPS -4.99
Shares 75.55M
Beta 1.48
Inst. own 75%
Sep 25, 2014
Alnylam Pharmaceuticals Annual Stockholder Meeting - 9:00AM EDT - Add to calendar
Aug 4, 2014
Q2 2014 Alnylam Pharmaceuticals Earnings Release (Estimated) Add to calendar
Jul 29, 2014
Alnylam Pharmaceuticals Inc RNAi Roundtable: ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection
Jul 22, 2014
Alnylam Pharmaceuticals Inc RNAi Roundtable:�Advances in Delivery of RNAi Therapeutics
Jul 15, 2014
Alnylam Pharmaceuticals Inc "RNAi Roundtables" Webcast Series
Jun 24, 2014
Alnylam Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 11, 2014
Alnylam Pharmaceuticals at Goldman Sachs Healthcare Conference
May 15, 2014
Alnylam Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Q1 2014 Alnylam Pharmaceuticals Earnings Conference Call
May 8, 2014
Q1 2014 Alnylam Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -3032.54% -189.17%
Operating margin -3251.53% -197.05%
EBITD margin - -175.36%
Return on average assets -134.13% -25.20%
Return on average equity -164.29% -44.13%
Employees 165 -
CDP Score - -

Address

3rd Floor, 300 Third Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. In March 2014, the Company acquired Merck's wholly owned subsidiary Sirna Therapeutics, Inc.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Laurence E. Reid Ph.D. Senior Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 39
Bio & Compensation  - Reuters
Amy W. Schulman Director
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 60
Bio & Compensation  - Reuters
Steven M. Paul M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters